In an October 2018, trial in West Virginia, a federal jury found that Boehringer Ingelheim Pharmaceuticals Inc. was not forthright about the risk of potential bleeding injuries with its drug, Pradaxa (Dabigatran). The jury awarded the plaintiff $250,000 for medical expenses and pain and suffering, as well as $1 million in punitive damages. This was the first trial win for plaintiffs, after the manufacturer had succeeded at three prior trials. Boehringer Ingelheim Pharmaceuticals, Inc. has appealed the verdict.
Continue Reading Pradaxa (Dabigatran) Trials Continue Nationwide
Pradaxa
Boehringer Ingelheim Sanctioned Again in Pradaxa Litigation
As we have previously reported, Boehringer Ingelheim, the manufacturer of Pradaxa, has been sanctioned during the course of the federal litigation for destroying relevant documents. In a recent Case Management Order, Judge David R. Herndon, Chief Judge United States District Court, presiding over the litigation, revisited the manufacturer’s misconduct and fixed new sanctions.
In…
First Two Bellwether Trials in Pradaxa Litigation Scheduled
The use of Pradaxa has been linked to serious injury. There are nearly 2,000 cases currently pending in federal court in the Southern District of Illinois. Pradaxa is a blood thinner that was marketed to replace warfarin, a commonly used anticoagulant. Unfortunately, there is no readily-available antidote for the internal bleeding that can sometimes occur…
Court Orders Boehringer Ingelheim to Unseal Confidential Documents
The use of Pradaxa has been linked to serious injury. There are nearly 2,000 cases currently pending in federal court in the Southern District of Illinois. Pradaxa is a blood thinner that was marketed to replace warfarin, a commonly used anticoagulant. Unfortunately, there is no readily-available antidote for the internal bleeding that can sometimes occur…
FDA Announces New Safety Assessment for Pradaxa
The dangers associated with Pradaxa use are well known. Since reaching the United States’ market in 2010, Pradaxa has been linked to hundreds of deaths. The Food and Drug Administration (FDA) has received numerous adverse event reports for injuries and complications from Pradaxa use.
Physicians and analysts have commented that the health risks associated with…
Boehringer Ingelheim Sanctioned $931,000 for Destroying Documents
The use of Pradaxa has been linked to serious injury. There are nearly 2,000 cases currently pending in federal court in the Southern District of Illinois. Pradaxa is a blood thinner that was marketed to replace warfarin, a commonly used anticoagulant. Unfortunately, there is no readily-available antidote for the internal bleeding that can sometimes occur…
Court to Select Bellwether Cases in Pradaxa Federal MDL
As we have previously reported, the use of Pradaxa has been linked to serious injury. There are nearly 600 cases currently pending in federal court in the Southern District of Illinois. Pradaxa is a blood thinner that was marketed to replace warfarin, a commonly used anticoagulant. Unfortunately, there is no readily-available antidote for the…
Warning Added to Pradaxa for Blood Condition
As we have previously reported, the use of Pradaxa has been linked to serious injury. There are nearly 600 cases currently pending in federal court. The lawsuits allege that Pradaxa, manufactured by Boehringer Ingelheim, Inc., has resulted in devastating and sometimes fatal outcomes. Pradaxa is a blood thinner that was marketed to replace warfarin…
Pradaxa Manufacturer Ordered to Produce Employee Records
As we have previously reported, the use of Pradaxa has been linked to serious injury. There are nearly 600 cases currently pending in federal court. The lawsuits allege that Pradaxa, manufactured by Boehringer Ingelheim, Inc., has resulted in devastating and sometimes fatal outcomes. Pradaxa is a blood thinner that was marketed to replace warfarin…
Pradaxa Lawsuits Move Closer to Trial
As we have previously reported, the use of Pradaxa has been linked to serious injury. There are nearly 600 lawsuits pending in federal court. The Multi District Litigation (MDL), centralized in a Chicago federal court, continues to move forward. The next Status Conference in the Pradaxa litigation has been schedule for the middle of…